Tricyclic compounds as anticancer agents

US9725449B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Derek J. Norris · Pennington, US
• Wayne Vaccaro · Yardley, US
• Mikkel V. Debenedetto · Shrewsbury, US
• Andrew P. Degnan · New Haven, US
• George V. DeLucca · Wilmington, US
• Jeffrey A. Deskus · Marlborough, US
• Wen-Ching Han · Newtown, US
• Godwin Kwame Kumi · Morrisville, US
• William D. Schmitz · Cheshire, US
• John E. Starrett, Jr. · Middletown, US
• Matthew D. Hill · Wallingford, US
• Hong Huang · Longbeilingcun, CN

Key dates

• Filing date: May 10, 2016
• Grant date: Aug 8, 2017
• Expiry date: May 10, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to tricyclic compounds of the formulawherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.